Ir-Catalyzed Reversible Acceptorless Dehydrogenation/Hydrogenation of N-Substituted and Unsubstituted Heterocycles Enabled by a Polymer-Cross-Linking Bisphosphine
作者:Deliang Zhang、Tomohiro Iwai、Masaya Sawamura
DOI:10.1021/acs.orglett.0c01905
日期:2020.7.2
Notably, this protocol is applicable to the dehydrogenation of N-substituted indoline derivatives with various N-substituents with different electronic and steric natures. A reaction pathway involving oxidative addition of an N-adjacent C(sp3)–H bond to a bisphosphine-coordinated Ir(I) center is proposed for the dehydrogenation of N-substituted substrates.
Detosylative (Deutero)alkylation of Indoles and Phenols with (Deutero)alkoxides
作者:Ming-Hui Zhu、Cheng-Long Yu、Ya-Lan Feng、Muhammad Usman、Dayou Zhong、Xin Wang、Nasri Nesnas、Wen-Bo Liu
DOI:10.1021/acs.orglett.9b02639
日期:2019.9.6
An efficient strategy for N/O-(deutero)alkylation of indoles and phenols with alkoxides/alcohols as the alkylation reagents is described. The consecutive detosylation/alkylation transformations feature mild reaction conditions, high ipso-selectivity, and good functional group tolerance (>50 examples). A one-pot selective N-alkylation of unprotected indoles with alcohols and TsCl is also realized. The
Studies on the Preparation of 2-Indolyl Triflates and Related Compounds
作者:Samuel C. Conway、Gordon W. Gribble
DOI:10.1080/00397919208021125
日期:1992.11
Abstract Upon treatment with trifluoromethanesulfonic acid anhydride (triflic anhydride), oxindole (4) is converted into 1-(trifluoromethanesulfonyl)indol-2-y1 trifluoromethanesulfonate (10) in 70% yield. Some attempted reactions of 1-(trifluoromethanesulfonyl)indole (13), conveniently prepared by treating indole (12) with n-butyllithium and triflic anhydride, are described.
[EN] INDOLE DERIVATIVES AS CRAC MODULATORS<br/>[FR] DÉRIVÉS D'INDOLE UTILISÉS COMME MODULATEURS DE CRAC
申请人:HOFFMANN LA ROCHE
公开号:WO2011036130A1
公开(公告)日:2011-03-31
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).